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Abstract
Semaphorins are secreted and transmembrane proteins that bind plexin/
neuropilin or integrin receptors, providing paracrine axonal guidance signals and 
ultimately leading to a functional and developed neuronal network. Following 
semaphorin’s initial discovery, their relevance in the central nervous system (CNS) 
soon intrigued researchers about the possible links between semaphorins, their 
receptors and signaling mechanisms and different neurodegenerative diseases. 
Here, we explore the current knowledge of semaphorin’s function and signaling in 
Alzheimer’s disease (AD), Parkinson’s disease (PD), Charcot-Marie-Tooth disease 
(CMT), amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Human 
T-cell lymphotropic virus type 1 (HTLV-1)-associated myelopathy/tropical spastic 
paraparesis (HAM/TSP). We focus on the effects of the most known semaphorin 
subclasses 3A and 4D, yet extending our discussion to other semaphorins that 
have been found involved in specific neuropathologies and the potential effect 
of semaphorins modulating the immune system in disorders with inflammatory 
components. Molecular, cellular, and genetic evidences are reviewed, highlight-
ing the relevance of semaphorins on each disease etiology, pathophysiology, and 
progression. The newly discovered semaphorin functions in neurological disorders 
even suggest alternative therapies that may be highly valuable in diseases that have 
no current cure.
Keywords: semaphorin, neuropilin, plexin, neuroimmune cross talk, 
neurodegeneration
1. Introduction
Semaphorins (Sema) are a large family of proteins originally discovered as 
axon guidance signals during development as signals toward proper innervation of 
targets [1]. Semaphorin function is fundamental during embryonic development, 
yet they are also largely expressed in the adult brain. In the past decades, an increas-
ing amount of evidence shows that semaphorins participate in refining synapto-
genesis, dendritic and axonal exuberance, remodeling of the synaptic network, 
and even modulating neuronal response to reactive oxygen species and neuronal 
apoptosis. The association of semaphorins to neuronal function and cell death was 
soon explored in the context of neurological diseases [2–6]. Several reports linking 
alteration of semaphorin function or expression in neuropathologies opened an 
unexplored door to understand the mechanisms and look for treatment alternatives 
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of disorders with unknown or poorly understood pathological origins. Here, we 
aim to summarize the state of the art involving semaphorins on Alzheimer’s disease 
(AD), Parkinson’s disease (PD), Charcot-Marie-tooth disease (CMT), amyotrophic 
lateral sclerosis (ALS), multiple sclerosis (MS), and Human T-cell lymphotropic 
virus type 1 (HTLV-1)-associated myelopathy/tropical spastic paraparesis (HAM/
TSP caused by HTLV-1 infection).
The role of semaphorins in neurological diseases depends on the different types 
of semaphorins, their receptors, different signaling pathways they activate, and the 
neuronal context [1]. For instance, some semaphorins are considered axon repellent 
in a particular neuronal context/disease, while chemoattractant in others. Similarly, 
some semaphorins are toxic to neurons and promote apoptosis, while others are 
neuroprotective. The bifunctionality of semaphorins is mirrored in a myriad of 
neurological affections and, therefore we, by no means, attempt to provide the 
reader with a complete list of diseases affected by Sema signaling or a thorough 
understanding of the Sema family members, their receptor, and their signaling 
pathways (refer to [2] instead), but rather provide an introductory reading for 
understanding semaphorin function in neurological pathologies.
1.1 Neurological disorders and the common factor of semaphorin
Neurological disorders of the central nervous system (CNS) are diseases with 
structural, biochemical, or electrical abnormalities in the brain and spinal cord 
caused by gene mutations, neuron damage, dysfunction of axon-dendrite connec-
tions, myelin loss, and/or damage of the surrounding vascular system. Neurological 
disorders include AD, PD, CMT, and ALS, sometimes showing an important 
immune component as MS and HAM/TSP [7, 8]. Currently, semaphorins are 
related with health and disease in the cardiovascular, immune, and central nervous 
systems. Although neurological disorders have different pathological origins, the 
participation of Sema signaling is a common factor [1, 9, 10]. Activation of sema-
phorin receptors in the neuronal growth cone promotes changes of cytoskeletal 
dynamics, resulting in an axon extension alteration and therefore possible neuronal 
dysfunctions in the context of neuropathologies [1, 11].
2. Semaphorin signaling
Semaphorins are a family of eight different subclasses with several members each, 
grouped based on amino acid sequence and structural similarities. Semaphorins 
include secreted and membrane-bound glycoproteins that bind mainly to plexin recep-
tors (most relevant semaphorins related with neurological disorders are summarized 
in Table 1) [1, 2]. Plexins (PLXN) are a family of nine types of transmembrane sema-
phorin receptors (plexins A1, A2, A3, A4, B1, B2, B3, C1, and D1). Class 3 semaphorins 
bind to neuropilins (NRP1 and NRP2) that act as co-receptors forming an heterocom-
plex with type A plexins (the transducing unit), and in some cases, the Sema3-plexin-
neuropilin complex may also associate with cell adhesion molecules of the IgCAM 
superfamily. Class 7 semaphorins bind to integrin receptors instead of plexins and 
neuropilins [1–3, 11–15]. While plexins seem to act as receptors for semaphorins only, 
the cell surface NRP receptors have pleiotropic functions, being also co-receptors for 
vascular endothelial growth factor (VEGF). NRP1 has high affinity for VEGF-A and 
is required for signal transduction after association to the VEGF receptor [16, 17]. 
Competition between VEGF and Sema3A for partially overlapping binding sites on 
NRP1 may produce a signaling unbalance potentially involved in neuropathologies.
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Once semaphorins bind to their receptors, the transducing unit triggers signal-
ing pathways linking several protein kinases and downstream substrates that over-
all change microtubule and actin dynamics, promoting growth cone collapse and 
axon repulsion in neurons. Nevertheless, changes in the neuronal environment 
or the type of semaphorin/receptor complex may shape a different transduction 
effect. Plexin receptors contain a cytoplasmic region acting as a GTPase-activating 
protein to bind and stimulate GTPase activity of Rho, Rac1, Rnd1, and R-Ras 
proteins. For instance, the G-protein R-Ras is involved in neuronal sprouting and 
cell adhesion via activation of integrins. Semaphorin signaling via plexin A1/B1 
inactivates R-Ras. Sema3A- and Sema4D-mediated signaling, therefore, inhibit 
integrin β1 subunits through downregulation of R-Ras, leading to a reduction of 
growth cone adhesion and allowing collapse responses [1, 2, 10, 15]. Another cen-
tral protein participating in semaphorin-induced growth cone collapse signaling 
is collapsin response mediator protein-2 (CRMP-2). CRMP-2 is a phosphoprotein 
mostly expressed in the CNS and involved in the cytoskeleton structure and func-
tion of neuronal cells through the induction of microtubule dynamics/assembly 
by binding to α- and β-tubulin heterodimers. The complex CRMP-2/kinesin-1 
regulates soluble tubulin transport to the distal part of the growing axon and also 
neurite formation by modulating tubulin GTPase via intramolecular interaction 
with its N-terminal inhibitory region [18–20]. The affinity of CRMP-2 for tubulin 
is significantly diminished when specific residues are phosphorylated, leading to 
axon retraction and growth cone collapse [21, 22].
Sema Disease Receptors/coreceptors Cell 
expression
Functions
Sema2A CMT Plexin B
Sema1A
Neurons Neuronal connectivity, cell 
migration
Sema3A
Sema3B
Sema3C
Sema3D
Sema3E
Sema3F
AD, PD,
ALS, MS
Plexin A1-4/Nrp1/Nrp2, 
IgCAM, RTK, integrins, 
proteoglycans VEGFR2
Neurons, 
glia, immune 
cells
Cytoskeletal organization, 
neuronal connectivity, 
regeneration, synaptic 
transmission, regeneration, 
cell migration, angiogenesis, 
immune responses
Sema4A
Sema4D
MS, HAM/
TSP
Plexin B1/Met, ErbB2, 
Timp2, RTK
Neurons, 
glia, immune 
cells, 
endothelial 
cells, thymus
Cytoskeletal organization, 
neuronal connectivity, 
angiogenesis, cell migration, 
synaptic transmission, 
regeneration, immune 
responses
Sema5A AD, PD, Plexin B3/Nrp2, CSPGs, 
HSPGs, TK
Neurons, glia Cytoskeletal organization, 
neuronal connectivity, 
synaptogenesis, vascular 
patterning
Sema7A PD, MS b1-integrins, α,b- 
integrins, plexin C1
Neurons, 
glia, immune 
cells, 
fibroblasts, 
thymus
Cytoskeletal 
organization, cell 
migration, cell adhesion, 
immunomodulation, 
stimulating cytokine 
production, 
proinflammatory responses
Receptors [1, 2, 10, 12, 15], cell expression [9, 10] functions [9], and diseases discussed here are indicated.
Table 1. 
Semaphorins in neurological diseases.
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3. Semaphorin regulatory functions on neuronal and non-neuronal cells
3.1 Axonal degeneration associated to cytoskeleton organization
The roles of Sema3A and Sema4D are to produce alteration of both actin and 
microtubule dynamics in the cytoskeleton organization (ratio of the polymerization/
depolymerization rates). The effects of Sema3A and Sema4D on actin dynamics 
include the downregulation of PI3K-Akt signaling pathway, inhibiting integrin-
mediated adhesion as well as repulsive effects on axonal growing associated to 
actin-rich structure loss of lamellipodia and filopodia as part of the cofilin pathway 
triggered by Sema3A, or activation of myosin II (MyoII) and F-actin bundles 
promoted by Sema4D-ROCK signaling [2, 23, 24]. Sema3A additionally mediates an 
increase of the nonphosphorylated active form of myosin II (MyoII) and decreases 
the phosphorylation levels of Ezrin, Radixin, and Moesin (ERM) proteins. The 
nonphosphorylated active form of MyoII promotes retraction, while low ERM 
phosphorylation reduces the crosslinking between actin filaments and the plasma 
membrane [2, 25, 26]. Regarding microtubule dynamics, Sema4D signaling induces 
the inactivation of CRMP-2 by glycogen synthase kinase 3 beta (GSK3B)-mediated 
phosphorylation, leading to reduced binding of CRMP-2 to tubulin and consequently 
limiting its stabilizing function at the plus end of microtubules. Sema3A induces a 
similar CRMP-2-inactivating mechanism, yet requiring phosphorylation by cyclin-
dependent kinase 5 (Cdk5) at Ser522 and GSK3B at Thr509/514 [2, 21, 22].
3.2 Axonal degeneration associated to synaptogenesis and synaptic plasticity
Synapsis formation of the neuronal network requires local participation of 
cell adhesion molecules, extracellular proteins, and axon guidance molecules at 
axodendritic sites [6]. Sema3A and VEGF signaling have been proposed to actively 
modulate the synaptogenesis and synaptic plasticity, since they are dysregulated in 
neurological diseases, such as AD [4, 16, 17]. Proper regulation of the synapse for-
mation and dendritic branching contributes to a normal balance between excitatory 
and inhibitory synaptic transmission; dysregulation of this balance would interfere 
with the regeneration of damaged CNS axons [6, 11, 15, 27, 28].
3.3 Semaphorin function on axonal regeneration
Models of axonal regeneration have been studied after spinal cord injury, which 
can produce a permanent damage because axonal growth and regeneration are 
limited after injury [29]. In adult mammals, some myelin proteins produced by 
myelinating oligodendrocytes, such as Nogo-A, MAG and OMgp, inhibit spinal 
cord regeneration [4]. Additionally, glial cells release chondroitin sulfate proteogly-
cans (CSPGs) and lecticans, such as neurocan, brevican, phosphacan, and tenascin 
to form the neuronal extracellular matrix (perineuronal nets). The perineuronal 
nets, together with other extracellular proteins, such as, ephrins, slits, netrins, 
bone morphogenic proteins, Wnts, and semaphorins are among the molecules most 
likely involved in limiting axonal regeneration [4, 30–33]. However, the func-
tion of semaphorins is dependent on the cellular context and may also favor axon 
regeneration. For instance, nerve growth factor (NGF) co-injected with Sema3A in 
trigeminal neuronal cell culture induced neuron regeneration [34]. Sema3A has also 
been implicated in the restoration of functionally motor innervation required to 
regenerate fibers [35]. Sema4D has shown enhanced locomotor recovery and axon 
regeneration when expressed in motoneurons, attributed to regulation of microglia 
function following spinal cord injury in adult zebrafish [36].
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3.4 Semaphorin function on revascularization
Revascularization (restoration of perfusion) is regulated by several growth factors 
secreted from endothelial cells, such as VEGFA, FGF, and PDGFs [4]. Class 3 sema-
phorins are considered anti-angiogenic semaphorins (e.g., Sema3A, Sema3E, and 
Sema3F), because they interfere with the effect of VEGF by competing for the same 
NRP receptor [37, 38]. Sema3A not only targets the actin cytoskeleton, but also the 
assembly/disassembly of focal adhesions, altering migration, proliferation, and adher-
ence of endothelial cells [37]. Sema3A and Sema4D also produce alteration on the 
blood-brain barrier (BBB) by disrupting endothelial tight junctions and thus increas-
ing its permeability. BBB damage has been related to higher infiltration of immune 
cells mediated by increasing levels of Sema4D in MS [4, 39]. As opposed to Sema3A, 
Sema4D is pro-angiogenic and promotes endothelial cell migration via plexin-B1-
PI3K-Akt signaling pathway [37, 40].
3.5 Semaphorin function on remyelination
Axon myelination in the CNS is essential for regulating fast and slow axonal 
transport rates. Myelination requires interaction among axons, oligodendrocytes, 
and semaphorins. Semaphorins regulate the migration of oligodendrocyte precur-
sor cells (OPC) during normal development and toward demyelinated lesions. 
Demyelinization, caused by loss of oligodendrocytes and myelin sheaths around 
axons, is a pathological condition that results in axonal dysfunction, degeneration 
and loss of sensory and motors neurons  [2, 4, 41–43]. Oligodendrocyte death can 
be produced by genetic defects, infections, autoimmune reactions, and trauma, 
along with unknown causes. In some CNS pathologies related to myelination, 
astrocytes clear off myelin debris, modulating oligodendrocyte activity, myelin 
maintenance, and its synthesis [43]. Semaphorins (Sema3A, Sema4D, Sema5A, 
Sema6A, and Sema7A) inhibit OPC recruitment into demyelinated lesions and its 
differentiation to oligodendrocytes [9, 42, 44, 45]. Sema4D, Sema6, and Sema7A 
have been detected in myelin, and their expression found strongly upregulated in 
oligodendrocytes located near the injury site [9, 2, 45].
3.6 Semaphorin function on immune responses
Sema4D, formerly known as CD100, was called the “immune semaphorin” 
because it was originally found in lymphocytes [3]. The Sema4D receptor in 
neuronal cells is plexin B1, whereas in immune cells, besides binding to plexin 
B1, Sema4D also binds to a signaling surface receptor CD72. CD72 is considered 
a regulatory receptor, because it activates suppressive signals and prevents some 
forms of autoimmunity [46, 47]. Sema4D is a membrane-bound protein that can be 
proteolytically cleaved by MT1-MMP metalloprotease, releasing a 120-kDa soluble 
form of Sema4D, which can act paracrinally on other systems [40, 47]. Immune 
semaphorins also include Sema3A, Sema4A, Sema6D, and Sema7A expressed on 
T-cells, B-cells, natural killer cells, neutrophils, platelets, and mature dendritic cells 
(DC) [39, 47]. The neuronal system sense changes to maintain CNS homeostasis 
and communicates to the immune system by soluble factors to inhibit further 
inflammatory responses. For instance, neurons control T-cell and glia functions 
mediated by membrane-bound or secreted molecules such as semaphorins, neuro-
trophins, neurotransmitters, neuropeptides, and cytokines [48, 49]. Sema3A and 
Sema7A expression in neurons attenuate T-cell activation, proliferation, and func-
tion through T-cell receptor signaling [49–51]. Sema3A, additionally, downregulates 
autoimmunity by suppressing B- and T-cell-mediated autoimmune over-activity 
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responses [52]. In addition, cell adhesion molecules expressed by neurons, such as 
NCAM, cadherins, and integrins are active molecules in neurogenesis and synaptic 
plasticity that also can ameliorate inflammation and neurotoxic effects, while 
strengthening neuroprotection of immune components in pathology [48].
4. Semaphorins and their current association to neurological diseases
4.1 Alzheimer’s disease
Alzheimer’s disease (AD) is the most invalidating, common, and widespread 
elderly associated neuropathology. An estimated of over 30 million people are 
affected worldwide, increasing its incidence with age [53]. Patients with AD suffer 
progressive neuron lost, mostly from the prefrontal cortex and the hippocampus. 
As a consequence of neuronal death, patients experience memory, cognitive, and 
behavioral problems, leading within an average of less than 10 years to dementia 
and/or death [53]. Given its prevalence and the continuing aging of the population, 
AD threatens to generate an epidemic healthcare crisis in the next decades and yet 
its cause remains unknown. Current treatments target late symptoms, improv-
ing the patient’s quality of life; however, they have a minute contribution on the 
disease impact and its inevitable progression. Two major features are distinct from 
Alzheimer’s brains that have intrigued researchers since Alois Alzheimer described 
them in 1906: presenile plaques and neurofibrillary tangles (NFT). Plaques are 
extracellular insoluble aggregates, mostly composed of a misfolded amyloid beta 
(Aβ) peptide, whereas NFT are intraneuronal aggregates of hyperphosphorylated 
Tau (a microtubule-associated protein). It is yet controversial whether tangles, 
plaques, or both are causes or consequences of AD. Semaphorins have been long 
suggested to play a role in AD, because they initially were found largely expressed in 
adult brain tissues [54] and later found to have abnormal neurohistological patterns 
in affected cortical and hippocampal areas of AD brains [55], especially on vulner-
able neurons [56, 57].
It has been hypothesized that Sema3A may be involved in the early stages of 
Alzheimer’s degeneration. By analyzing the histological localization of Sema3A in 
vulnerable hippocampal areas that are first affected by neurodegeneration, a dys-
regulation in Sema3A expression and release has been proposed as a possible early 
sign in AD brains, observed even in neurons lacking NFT and therefore possible 
preceding Tau hyperphosphorylation and aggregation [57]. An intracellular form 
of Sema3A was also found associated to NFT, along with Plexins, hyperphosphory-
lated CRMP-2, and microtubule-associated protein 1B (MAP-1B) [57]. The associa-
tion between Sema3A and a possible downstream Tau hyperphosphorylation may 
come from the kinases involved in Sema3A signaling. Yoshida et al. initially found 
a phosphorylated form of CRMP-2 associated to NFT and significantly higher 
in AD brains [58]. CRMP-2 was originally discovered form its chicken homolog, 
CRMP-62, as a downstream effector of semaphorin (formerly known as collapsin) 
signaling. Injection of blocking antibodies against CRMP-62 into dorsal root 
ganglion inhibited the growth cone collapse induced by Sema3A, suggesting that 
CRMP-62 is a downstream effector in Sema3A signaling [59]. Since then, CRMP-2 
has been associated to NFT in AD [58] and found phosphorylated as a result of 
semaphorin signaling [60, 61]. The signaling mechanism involves phosphoryla-
tion of CRMP-2 by GSK3B after a priming phosphorylation at Ser522 [61, 62]. The 
phosphorylation at Ser522 is required for further phosphorylation of GSK3B. In 
rat models, Cdk5 has been found responsible of Ser522 phosphorylation, priming 
the phosphorylation site of GSK3B both in vitro and in vivo [63, 64]. The sequential 
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phosphorylation of CRMP-2 reduces its affinity to tubulin and triggers microtu-
bule destabilization and Sema3A-mediated growth cone collapse associated to AD 
pathogenesis [63, 64]. Other kinases, such as Fyn, cyclin-dependent kinase 1, and 
dual specificity tyrosine-phosphorylation-regulated kinase 2 may also be involved 
in the priming phosphorylation at Ser522 [61, 64, 65]. The participating kinases 
and the Sema3A-mediated sequential phosphorylation mechanisms of CRMP-2 are 
strikingly similar to the pathway leading to Tau hyperphosphorylation, aggrega-
tion, and microtubule destabilization observed in AD [66].
A recent study also links Tau phosphorylation to Sema3A signaling by discovering 
several single-nucleotide polymorphisms (SNPs) associated to AD in the PLXNA4 
gene, which codifies for plexin A4 [62]. Most of the top-ranked SNPs associated to 
AD were located in the region coding the Sema3A-binding site [62]. Cells expressing 
PLXNA4 and stimulated with Sema3A showed Sema3A-induced phosphorylation 
of Tau, enhanced by overexpression of the full-length PLXNA4 receptor, whereas 
expression of soluble forms of PLXNA4 inhibited Tau phosphorylation, presumably 
by binding Sema3A and competing with the endogenous Plexin receptor, both in a 
cell line model and in rat hippocampal neurons [62]. The full-length PLXNA4 expres-
sion was found higher in AD brains, and also significantly correlates with clinical and 
neuropathological disease severity measures, such as dementia. The Sema3A-induced 
kinase activities affecting CRMP-2 and Tau may ultimately lead to neurofibril-
lary tangle formation and neuronal dead in AD. If Sema3A signaling is effectively 
involved in the early stages of neurodegeneration, it would be worth to further study 
its association with AD toward the discovery of new biomarkers and drugs, such as 
specific kinase inhibitors (some of them already in clinical trial) [67]. An example of 
a different treatment approach involves modulating the interaction of semaphorins 
with the neuronal extracellular matrix or perineuronal nets. Differential expression 
of several proteins related to the extracellular matrix, among them Sema3C, has been 
found in AD-vulnerable brain areas [56]. Additionally, memory restoration in AD 
mice models has been achieved by digesting CSPs, a major component of perineuro-
nal nets, using chondroitinase [68, 69]. Disruption of perineuronal nets presumably 
allows the formation of new synapsis sites and thus increases adult brain plasticity. 
An important effector of perineuronal nets is Sema3A by binding to chondroitin 
sulfate, a main component of CSPs [70]. A recent study showed restoration of object 
recognition memory in a tauopathy mice model via reducing Sema3A binding to peri-
neuronal nets by perirhinal cortex injections of an inhibitory proteoglycan-neutral-
izing antibody against chondroitin 4-sulfate [69]. Therefore, blocking the binding of 
Sema3A to perineuronal nets can restore memory function in adult AD-mice model.
It is also interesting to note the bifunctional effect of semaphorins in AD. For 
instance, Sema3A has been shown to promote apoptosis and neurodegeneration [57, 
61], whereas Sema3C has been related to neuroprotection [56, 71]. Such duality, 
along with several other genetic, environmental, and aging components, gives to 
AD its multifactorial category. Genetic factors are thought to account for over 50% 
of the disease, yet these risk factors are not determinants to causing AD. In rare 
cases of early-onset familial AD, the disease is linked to mutations on genes involv-
ing Aβ metabolism, such as the amyloid precursor protein (APP) and presenilin 
(PSEN1/2) genes. APP is a transmembrane protein from which Aβ peptide is gener-
ated by the cleavage of a gamma secretase complex. Presenilin-1 and presenilin-2 
are part of the gamma secretase complex. However, in the most common sporadic 
(nonfamilial) late-onset AD, the genetic variants only explain part of the disease 
etiology. Several genes have been considered a risk factor, such as the APOE-ε4 
polymorphic isoform of the apolipoprotein E gene (APOE), the main cholesterol 
carrier in the CNS. The role of apolipoprotein E in AD is, however, poorly under-
stood and thought to be related to Aβ degradation [72]. Semaphorin polymorphs 
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have also been studied given their relevance in neuronal apoptosis and the findings 
of semaphorin polymorphisms related to other syndromes. The first attempts in 
relating semaphorin SNPs with AD were, however, unfruitful. Evaluation of two 
exonic SNPs of semaphorin 3A and 4D genes in patients with AD showed no cor-
relation, even though modeling analysis predicted a damaged variant of the affected 
proteins [73]. Recently, however, a novel proposed method for detecting hidden 
SNPs that would otherwise appear undetected by commonly used tests found six 
SNPs on noncoding regions near the semaphorin 5A gene [74]. Schott et al. [75] also 
found in a noncodifying region of the SEMA3C gene a polymorphism associated to 
posterior cortical atrophy, a variant of AD. The SEMA3C SNP, therefore, suggests 
a role of Sema3C during development that may influence later neurodegeneration 
associated to specific brain regions that ultimately lead to differential degeneration 
phenotypes [75]. In light of these recent associations of semaphorins to AD [62, 74, 
75], semaphorin gene variants and their receptors are expected to participate as a 
risk factor of AD and its associated neuropathologies, opening a relatively underex-
plored door toward new discoveries.
4.2 Parkinson’s disease
Parkinson’s disease (PD) is the second most prevalent neurodegenerative 
disorder after AD, affecting up to 1% of the worldwide population above 60 years 
old [76]. PD patients suffer a progressive and selective loss of dopaminergic 
neurons in the Substantia Nigra pars compacta (SNpc), which innervates neurons 
in the dorsal striatum and regulates its effects on motor functions. The result of 
neurodegeneration manifests mostly with movement disorders or dyskinesia, where 
tremor at rest, rigidity, and bradykinesia are cardinal for diagnosis [76]. The reason 
why SNpc dopaminergic neurons die is not well understood. A composite interac-
tion between genetics and environmental factors in the context of aging has been 
intensively studied to find the causes, preventing strategies and potential therapies 
of PD. Semaphorins in their role of apoptotic mediators in neurodegeneration have 
early on been suggested to be involved in the pathogenesis of PD [77–80].
Even though it is currently accepted that genetic plays a minor role in sporadic 
(nonfamilial) PD based on studies with relatives [81], several genes are known 
to be involved in the disease etiology and progression. For instance, mutations in 
the SNCA gene are known to be associated with familial PD and increased risk of 
sporadic PD. The SNCA gene encodes alpha-synuclein, which is the main protein 
found in Lewy bodies as insoluble aggregates inside SNpc neurons of patients with 
PD. Interestingly, population genetic studies have also found SNPs in the Sema5A 
gene that may be related to PD. In the pioneer work of Maraganore et al., 11 SNPs 
were associated to PD in Caucasian Americans by using a two-stage whole-genome 
association analysis including 198,345 SNPs. The SNP with the lowest p-value asso-
ciated to increased risk of PD was located in the Sema5A gene (rs7702187 polymor-
phism, corresponding to a thymine substituted by adenine in an intronic sequence) 
[82]. Given the relevance of semaphorins in neuronal apoptosis, the polymorphism 
in Sema5A found by Maraganore et al. [82] was soon assessed by different research 
groups, though having conflicting results that still remain unclear. The controver-
sies may come from the different populations evaluated in each analysis. Some stud-
ies have shown that the rs7702187 polymorphism is not associated to PD [83, 84] 
or even conflict to the extent of finding the polymorphic variant protective rather 
than a risk factor on a population-dependent basis [85]. Taiwanese Asians showed 
significant associations of the Sema5A rs7702187 polymorphism [85], whereas 
Finnish Caucasians, Polish Caucasians, Singapore Asians, and Chinese Han popula-
tions were not associated to PD [83–86]. In addition, a different SNP, the rs3798097 
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(C > T), located in the 5’UTR of the Sema5A gene, was also found associated with 
PD [85]. Ding et al. [86] showed that although the genotypes are not necessar-
ily associated to PD in a Chinese Han population, the haplotypes involving these 
two SNPs in the context of a particular ethnicity may be implicated in the disease 
by finding the AC haplotype associated with an increased risk of PD compared 
to the common TC haplotype, whereas the AT haplotype was found protective 
against PD [86]. A more recent meta-analysis on the rs7702187 polymorphism 
concluded that the A allele frequency was associated to increased risk of PD only 
in Western population [87]. Both polymorphisms do not affect the sequence of the 
protein, but rather may be regulatory sequences affecting expression dynamics of 
Sema5A. These SNPs may be associated to PD; however, less studied polymorphic 
variants together with other cellular and molecular factors should be considered 
as well, such as the expression of other semaphorin classes and their receptors that 
may result as a confounding factor across different population genetic studies.
Besides the genetic highlights on PD, the mechanisms by which semaphorins 
participate in the disease etiology and progression are poorly understood. Although 
semaphorins had been suggested to promote neurodegeneration in PD, limited 
studies were known to link semaphorins in the context of the disease pathogenesis 
[77, 78, 88, 89]. After a decade of research since the study of Maraganore et al. 
[82], several lines of evidence indicate possible direct mechanisms of semaphorins 
(though, not Sema5A) in PD etiology. Recent evidence in a neurotoxin (MPTP)-
induced PD mouse model directly involves Sema3A effects through Rho-ROCK 
signaling pathway. Rho kinase inhibition as well as heterozygous mice knockouts 
in both Rho and ROCK protect from MPTP-induced damage of dopaminergic 
neurons, increase dopamine and its metabolic products at the striatum, showed 
reduced protein expression of Sema3A and its receptors, plexin A and NRP-1, and 
overall alleviate the behavior damage compared to control PD mice [90–93]. The 
effects of Sema3A on Rho-ROCK signaling pathway could mediate several cyto-
skeleton effectors, contributing to growth cone collapse as well as regulation of 
neuronal apoptosis. Animal models and SNpc of human brains from PD-affected 
subjects show apparent neuronal apoptotic processes, probably triggered by oxida-
tive stress [94]. Whether semaphorins are directly involved in causing neuronal 
apoptosis in PD is debatable and may be associated in part to their specific recep-
tors and signaling pathways. For instance, although Sema3A through plexin A/
NRP-1 and activation of Rho kinase was found to promote dopaminergic damage 
[92], Sema7A has been found protective against ROS-mediated neurodegeneration 
[95]. Sema7A binds to integrin receptors and could potentially regulate apoptosis 
through different mechanism. Sema7A reduces the large axonal arborization 
on dopaminergic neurons, which potentially decreases mitochondrial oxygen 
demand, ROS production, and neuronal vulnerability observed in PD [95]. 
However, even different ligands to the same receptor for Sema3A have been found 
protective against neuronal apoptosis. For instance, VEGF shows neuroprotec-
tion in PD models likely by binding to neuropilin receptors, though it is unclear 
whether the downstream VEGF signaling effectors differ from the semaphorin 
transduction pathway or VEGF indirectly promotes protection by competition to 
the same receptor. Alternatively, VEGF could mediate apoptosis by other processes 
such angiogenesis [89]. It would be interesting to evaluate in future research 
different ROS-mediated apoptotic pathways and their interplay with semaphorin-
induced signaling, such as the phosphorylation targets of ROCK resulting in 
growth cone collapse (which could mediate CRMP-2 phosphorylation by a similar 
mechanism to what described previously for AD), to find out how these pathways 
are regulated in an effort to evaluate new drug candidates for PD prevention and 
treatment.
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Paradoxically, the Sema3A found to promote neurodegeneration in PD patho-
genesis, at the same time may be useful for steam cell transplantation therapy in 
PD patients [96–99]. Given that semaphorins participate in the formation of the 
nigrostriatal pathway during prenatal development, they have also been proposed 
to guide axons to their appropriate targets after possible cell replacement therapy 
with dopaminergic neurons [96, 100–105]. Embryonic stem cells differentiated 
to tyrosine hydroxylase-expressing neurons have been shown to have similar 
phenotype, expression of neuropilins, and response to Class 3 semaphorins than 
embryonic ventral mesencephalon neurons [96, 97, 106]. Via neuropilin-mediated 
signaling, Sema3A increases axonal length in collagen gel coculture experiments. 
Sema3C, besides increasing length, also attracts axons, whereas Sema3F produces 
either no effect or axon repulsion [96, 97]. Semaphorin axonal guidance results are 
promising toward the recovery of parkinsonian symptoms in transplanted PD ani-
mal models [98, 99]. Therefore, even though semaphorins may be directly involved 
in promoting PD neurodegeneration, they could also be a strategy to restore the 
dopaminergic function by providing axon guidance cues after embryonic stem cell 
intranigral transplantation.
4.3 Charcot-Marie-Tooth disease
Charcot-Marie-Tooth disease (CMT) is an inherited peripheral neuropathy 
associated with mutations in more than 90 different genes. CMT is divided into dif-
ferent forms based on the inheritance pattern and neurophysiological observations. 
The most common types are autosomal-dominant forms, and they are categorized 
into demyelinating with reduced nerve conduction velocities (CMT type 1) and 
axonal-loss type with relatively normal nerve conduction velocities (CMT type 2). 
Patients with CMT type 2 comprise about 20% of all cases [107–110].
Mutations in the gene GARS, encoding glycyl-tRNA synthetase (GlyRS), have 
been related to peripheral nerve degeneration and CMT type 2 [111]. In addition, 
mutated GlyRS has shown to bind neuropilin-1 in mice [112]. Besides its house-
keeping intracellular function during protein synthesis, GlyRS can be secreted and 
produce different cellular effects from the extracellular space [113]. In Drosophila, 
the Cader lab showed that mutant GlyRS is secreted by muscles and interacts with 
the neuromuscular junction [114]. Recently, they showed that the P234KY mutant 
version of GlyRS (mutation associated to CMT type 2) colocalizes with plexin B in 
presynaptic neurons. Also, Sema2A overexpression, but not Sema1A overexpres-
sion, decreased the effect that mutant GlyRS produced on muscle contraction, 
suggesting that plexin B signaling could be affected by mutated GlyRS by com-
petition with Sema2A [115]. Also, other ligands for neuropilin should be taken 
into account, such as VEGF. He et al. suggest that CMT type 2 mutations in GlyRS 
promote its abnormal binding to neuropilin-1, antagonizing the binding of VEGF 
and blocking the VEGF/neuropilin-1 signaling essential for survival and function 
of motor neurons [112]. Nevertheless, the neuropilin sequestration by mutant 
GlyRS has shown to be less detrimental in other tissues, given that this abnormal 
interaction is permissive to maturation and maintenance of the vasculature in 
CMT type 2 mice [116].
It is important to consider that in addition to the extracellular function, mutated 
GlyRS can have abnormal intracellular functions that could also contribute to the 
CMT pathogenesis, suggesting that multiple mechanisms could be participating. 
For example, human GlyRS mutations related to CMT (S581 L and G598A E71G, 
L129P, S211F, G240R, E279D, H418R, and G526R) have shown to have a gain-of-
function effect binding to histone deacetylase 6 (HDAC6) and enhance its function, 
promoting α-tubulin de-acetylation and leading to axonal transport deficit. It is 
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relevant to highlight that G598A patients have more severe distal weakness and 
wasting in the lower limbs, and in that same article, this mutation showed one of 
the strongest affinities for HDAC6 [117]. Thus, the most severe mutations in GlyRS 
could eventually promote abnormal interaction with both NRP1 and HDAC6. A 
combination of intracellular and extracellular effects could eventually explain 
the severity and early-onset clinical symptoms of the patients carrying the G598A 
mutation, as the authors suggested. Future experiments will have to address in more 
detail the contributions that different plexin/neuropilin ligands may have in CMT, 
and also link the phenotypes with abnormal activation or deactivation of transduc-
tion pathways controlled by these receptors.
4.4 Amyotrophic lateral sclerosis
ALS is a neurological disorder with motor neuron degeneration. Neuron loss 
leads to paralysis in muscles and death mostly by respiratory failure. Most of the 
studies in animal models related to ALS use superoxide dismutase (SOD) mutations 
in mice (in particular, the SOD1G93A transgenic mouse), although the mechanism 
by which SOD mutations cause ALS is not clear. In these mice models, modifications 
in axons and nerve terminals are observed even before the clinical symptoms [118].
The first report linking semaphorins and ALS was published in 2006 by De 
Winter et al. showing increased Sema3A mRNA levels in the SOD1G93A transgenic 
mice model [119]. Nevertheless, a more recent report from the same lab showed that 
ALS mice expressing a mutant version of Sema3A (K108 N mutation that produces 
diminished signaling capacity) had no difference in ALS-induced decline in motor 
behavior, contrary to what was initially expected [120]. These last results point to a 
minor contribution of Sema3A to ALS pathology, although other articles are in clear 
contradiction with this claim. A clear example is the article published by Venkova 
et al. who hypothesized that Sema3A is able to trigger distal axonopathy and muscle 
denervation in the SOD1G93A mouse model of ALS [121]. They propose that 
Sema3A released from terminal Schwann cells activates plexin-A/neuropilin-1, pro-
moting the regulation of kinases such as CDK5 and GSK3B that could alter CRMP-2 
phosphorylation and leading to microtubule instability and actin cytoskeletal 
rearrangements. The Sema3A-mediated signaling could inhibit compensatory axon 
sprouting and coordination of neuromuscular junction remodeling after injury, 
contributing to distal axonopathy [121]. Anti-neuropilin-1 antibodies that block the 
Sema3A docking site in differentiated motor neuron-like cells (NSC-34) prevented 
Sema3A-induced growth cone collapse. Furthermore, injections of blocking 
antibodies delayed and even temporarily reversed the motor functional decline 
while prolonging the life span of SOD1G93A mice. Histologically, the antibody 
reduced neuromuscular junction denervation and attenuated pathologic alterations 
in ventral roots at late stages of the disease [121] [121].
In parallel, Miyazaki et al. focused on extracellular protein changes in 
SOD1G93A mice during the development of ALS to characterize changes in the 
cellular environment that could affect regeneration [122]. They found decreased 
Sema3A levels in the anterior half of the lumbar cord of ALS mice. Sema3A 
immunochemistry at ages 15 and 18 weeks showed a progressive decrease of stain-
ing in the neuropil of ALS mice compared to wild type, while Sema3A-positive 
astrocyte appeared [122]. In addition, it was found that Sema3D gene expression 
levels are decreased 2.5-fold with respect to wild type in another ALS mouse model 
(SOD1G37R mutation) [123].
Another piece of evidence for the role of semaphorins on ALS is related to 
microribonucleic acids (miRNAs). miRNAs are small single-stranded, noncod-
ing RNAs that alter gene expression through post-transcriptional regulation by 
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binding to the 3′-untranslated region of target mRNAs [124]. The Perlson lab [125] 
analyzed miRNA profiles from axons and somas of two ALS mouse models, SOD1 
with G93A mutation and TDP43 with A315T mutation. They showed that different 
miRNAs were significantly altered in the axons expressing ALS mutations, but not 
in the somas, indicating that miRNA could be regulating local functions in motor 
neuron axons [125]. Later, the same lab using qRT-PCR showed that one of these 
miRNAs, miR126-5p, downregulates Sema3A, Sema3B, neuropilin-1, and neuropi-
lin-2 transcript levels in HeLa cells. Primary myoblasts with the SOD1G93A muta-
tion were transfected with miR126-5p and cultured in a distal compartment of a 
microfluidic chamber together with a motor neuron explant placed in the proximal 
compartment. They showed that in the microfluidic chamber, the rate of axons that 
traversed the distal compartment was increased respect to the control condition 
of myoblasts transfected with an irrelevant miRNA. In addition, the injection of 
miR126-5p to ALS mice increased the amount of intact neuromuscular junctions 
revealing higher innervation in treated muscles compared to the mock condition. 
Three parameters: Mean Stand Index (measurement of the speed at which the 
paws detach from the walking surface), single-support parameter (the relative 
duration of all combined paws in contact with the glass floor), and base of support 
parameter (the average width of limb spreading between front or hind paws) were 
measured in ALS mice, and in all cases, the injection of miR126-5p improved all 
parameters respect to the control [126]. Based on these observations and previous 
reports, the authors suggested an attractive model of Sema3A/neuropilin-1 interac-
tion that explains how the motor neuron degeneration in ALS could be regulated by 
miR126-5p. miR126-5p decrease in ALS could enhance Sema3A secretion in muscle 
and overexpression of neuropilin-1 in axons, increasing Sema3A signaling in the 
neuromuscular junction and leading to axon degeneration [126].
It is of consideration to test the results obtained with ALS mouse models in 
human samples. Motor cortex tissue samples showed increased Sema3A mRNA lev-
els by quantitative RT-PCR in ALS patients (eight cases aged 44–72 years) compared 
to control samples (six subjects aged 45–84 years, with no neurological disease 
history). Likewise, by immunohistochemistry, the motor cortex showed stronger 
cytoplasmic and axonal Sema3A labeling in motor neurons of ALS patients com-
pared to controls. Sema3A mRNA levels and immunohistological labeling showed, 
however, no difference between ALS patients and controls in spinal cord tissue 
samples [127]. Sema3A levels in human samples support the previous findings in 
ALS mouse models discussed above. However, other semaphorins and neurological 
factors not studied yet in the context of ALS may provide a better understanding of 
semaphorin function and mechanisms on ALS pathology.
4.5 Spastic paraparesis associated to HTLV-1
HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is 
produced by infection with the retrovirus HTLV-1 (Human T-cell lymphotropic 
virus type 1 (HTLV-1) [128, 129]. HTLV-1 is transmitted by breast-feeding, sexual 
intercourse, and parenterally [130]. Worldwide, around 15–20 million people 
are infected with HTLV-1; however, only 3–5% develop HAM/TSP. Another ~5% 
develop adult T-cell leukemia/lymphoma (ATL), whereas over 90% of infected 
people are asymptomatic carriers [131]. The most common HAM/TSP symptom 
is lower limb motor dysfunction, followed with bladder/bowel dysfunctions and 
sensory alterations [132]. The virus mainly infects CD4+-T-cells, while monocytes, 
B-cells, CD8+-T-cells, and DC are infected to a lesser extent and found in spinal cord 
lesions together with infected astrocytes and endothelial cells [7, 133]. HAM/TSP 
causes alteration of CNS axonal transport based on the presence of APP deposits 
13
Roles of Semaphorins in Neurodegenerative Diseases
DOI: http://dx.doi.org/10.5772/intechopen.82046
in the axons, a classical marker of defects in fast axonal transport [134, 135]. 
Immunological studies have shown a chronic infiltration of activated CD4+ and 
CD8+-T-cells into the CNS [136].
It is a consensus that the paraparesis axonopathy generates as a consequence of 
chronic extracellular action of viral proteins secreted by the infected lymphocytes 
present in the CNS [137, 138]. Among secreted proteins, Tax viral protein acts on 
several viral and cellular processes, modulates various cellular signaling pathways, 
and has also been detected in the CSF of HAM/TSP patients. In the cytoplasm of 
infected lymphocytes, Tax activates NF-kB pathway responsible for proliferation 
and differentiation of T-cells, whereas in the nucleus, Tax activates the ATP/CREB 
pathway. Tax can also be secreted via endoplasmic reticulum-Golgi apparatus and 
by exosomes [136–141]. Tax secreted from activated peripheral blood mononuclear 
cells (PBMCs) could explain the presence of Tax in the plasma and CSF of infected 
patients and carriers [141].
Using in vitro culture of PBMCs from HAM/TSP patients, it has been recently 
found that the levels of secreted Sema4D were increased compared to healthy 
subjects [142]. Elevated Sema4D could be explained as a result of increased levels 
of MT1-MMP—the enzyme responsible for generating soluble Sema4D (Sema4D) 
from the transmembrane Sema4D—found in PBMCs from HAM/TSP patients. 
It has been also found that Tax and SEMA4D co-immunoprecipitate from PBMC 
culture medium. To test the effect of Tax and Sema4D (or the Tax/Sema4D 
complex) in neuronal cells, culture media from infected lymphocytes were added 
to PC12 cells during their differentiation to neuronal type, finding decreased 
neurite length as a result. The effect of HTLV-1-infected PBMC culture media was 
blocked by both anti-Sema4D and anti-Tax antibodies, suggesting neurite length 
reduction by a Tax/Sema4D complex [142]. In the same report, it was shown that 
infected lymphocytes strongly migrate in response to Sema4D using a trans-well 
system. It was found that in the population of migrated lymphocytes, the levels of 
CRMP-2 phosphorylation at Ser522 were increased [142]. A change in Sema4D-
mediated phosphorylation of CRMP-2 could be responsible for the increased 
motility. Authors proposed  that infected lymphocytes have an increased migra-
tory response toward Sema4D, making them able to cross the BBB [142]. Once 
in the CNS, infected lymphocytes secrete Tax and Sema4D, attracting more 
HTLV-1-infected lymphocytes at the same time that these proteins could mediate 
pathological disturbances on neuronal cells.
4.6 Multiple sclerosis
MS is a CNS disease mostly considered of autoimmune etiology. It shows 
demyelinated plaques that sometimes remyelinate spontaneously. Remyelination 
involves the recruitment of OPC, which differentiate into mature oligodendrocytes 
in damaged areas to promote remyelination. Nevertheless, the remyelination 
process is prone to fail, leading to progressive disability [41, 143]. Even though there 
are multiple reports linking semaphorins with lymphocyte signaling during MS; 
in this section, we will focus on discussing the reports that have linked semaphorin 
signaling in oligodendrocytes during MS.
Sema3 proteins are the main semaphorins related to MS, although there is an 
increasing evidence of Sema4 involvement as well. Using postmortem human 
samples, the Lubetzki lab [144] showed the presence of numerous cells positive 
for Sema3A or Sema3F transcripts around and within demyelinating white matter 
lesions in MS brains, whereas these transcripts were absent in control adult brain 
white matter. The differential expression of Sema3A and Sema3F was strictly 
restricted to active plaques. No expression was detected in normal white matter 
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distant to active lesions, around/within chronically demyelinated lesions or remy-
elinated plaques [144]. Later, also in human MS tissue samples, it was shown that 
although the chemoattractant Sema3F and chemorepellent Sema3A had similar 
protein expression patterns in some lesions, Sema3A was predominantly expressed 
in chronic active lesions, which mostly contain few OPCs [145].
The Lubetzki lab [42] also used a mouse model where demyelinated lesions are 
induced by lysophosphatidylcholine injection. They found that adult OPCs express 
Sema3 receptors (plexin A and neuropilin 1 and 2) and that the expression of these 
receptors, together with Sema3A and Sema3F, is increased after the induction of 
lesions. Interestingly, in vivo lentiviral expression of Sema3A decreased the OPC 
density in induced lesions, whereas Sema3F produced the opposite effect. When a 
transgenic mouse with a mutated NRP1 preventing Sema3A binding was used, an 
increase in OPC density was found after the induction of lesions compared to wild-
type mice. The density of remyelinated axons increased in lesions of animals receiv-
ing the Sema3F, but not the Sema3A lentiviral vector [42]. Using a similar approach, 
in a more recent publication 145, the authors injected recombinant Sema3A and 
Sema3F to mice. Sema3A-treated mice had significantly fewer OPCs on the side of 
the lesion compared to the opposite side without lesion, whereas Sema3F-treated 
mice had increased number of OPCs in the lesion side [145]. Parallel studies in rats 
have shown that Sema3A inhibits CNS remyelination and the lineage progression 
of OPCs in demyelinated lesions, arresting OPCs at a premyelinating state [44]. 
Finally, a recent report using exome sequencing analysis found an association of a 
missense mutation in the plexin A3 gene (receptor of Sema3A and Sema3F) with 
increased disability in MS males. Given the gender association, the authors debated 
whether the plexin A3 mutation could alter the protein stability, interfering with 
its ligand binding and arguing the possibility of protective effects of estradiol in 
females [146]. Considering that in MS lesions, Sema3A and its receptors are also 
expressed in neurons, reactive astrocytes, and microglia/macrophages [147], the 
source of Sema3A can be multiple and simultaneously affect not only OPCs signal-
ing, but also other cell types.
There are also some reports linking MS with Sema4. Ferritin uptake by oligo-
dendrocytes is mediated by the Tim2 receptor and required for iron acquisition. 
In addition to ferritin, Tim2 binds Sema4A [148]. Recombinant Sema4A exposure 
to primary rat OPCs resulted in dose-dependent OPC cytotoxicity. Astrocytes 
and mature oligodendrocytes were, however, unaffected. The authors suggested 
that the observed cytotoxicity could be mediated by Tim2 receptor. Lymphocytes, 
macrophages, or microglia could be the source of Sema4A in vivo [149]. Later, the 
same group found that human oligodendrocytes undergo apoptosis when exposed to 
Sema4A and that the levels of this protein are increased in multiple sclerosis patients 
[150]. A different research group used recombinant Sema4D in an in vitro model of 
cultured OPC, resulting in actin filament rearrangement indicative of cytoskeletal 
collapse, along with an increase in apoptotic cells and fewer OPC differentiating into 
mature oligodendrocytes. All these effects were avoided by incubation with anti-
Sema4D antibody [39]. The relative contribution of different semaphorins remains 
to be tested in future experiments in order to understand their role in the nervous 
system during MS.
4.7 Cross talk between the immune and the nervous systems
Even though the semaphorin signaling in lymphocytes is not the main subject 
of this chapter, it is impossible to completely dissociate the semaphorin signaling 
15
Roles of Semaphorins in Neurodegenerative Diseases
DOI: http://dx.doi.org/10.5772/intechopen.82046
in the nervous system from their roles in the immune system. The cross talk 
between these systems is extensive, and different neurological disorders are 
considered to have an important neuroinflammatory component. For example, 
the most commonly used animal model for MS is the experimental autoimmune 
encephalomyelitis (EAE) model, which resembles neuroinflammatory condi-
tions. Different authors suggest that the effect of semaphorins in the nervous 
system is most likely an indirect effect through modulation of the neuroinflam-
mation produced by immune cells in the nervous system, supported by using 
the EAE model. For instance, the EAE pathology is exacerbated in Sema7A-
deficient mice, and T cells are hyperactive in response to activation in this model. 
Similarly, Sema4A is increased in MS patients and associated to nonresponsive-
ness to IFN-β therapy. Anti-Sema4D antibodies inhibited neuroinflammation 
during EAE [151–153].
Most of the patients who later will develop MS, usually, have an acute episode 
of neurological disturbance known as clinically isolated syndrome (CIS). The 
Montalban lab [154], using mass-spectrometry analysis, identified proteins associ-
ated with conversion to MS in CSF samples from CIS patients in a follow-up study. 
They found that Sema7A was downregulated in patients who later converted to MS 
[154, 155]. Using the EAE model, the same group found that Sema3A is increased 
in the CNS and decreased in the immune system, whereas Sema7A is increased in 
both systems [156]. The above results suggest an intricated system where different 
semaphorins can be participating at the same time. It is important to understand the 
relative contribution of different neuronal types and different immune cell types to 
the pathology and also the amount of soluble semaphorins available to interact with 
these cells.
5. Conclusion and future perspectives
Throughout this chapter, we have reviewed the currently known implications of 
different semaphorin classes to some relevant neurological disorders, highlighting 
their receptors and signaling pathways that could be affected in neuropathologies. 
Even though the diseases we discussed here represent just a fraction among several 
other semaphorin-affected neurodegenerative, psychiatric, and immunological 
disorders, they are also likely representative of the semaphorin function. The 
advances so far in this field are promising, yet the results obtained from murine 
systems require testing on human models and subsequently, approaching to 
eventual therapies and clinical trials. We have already mentioned the potential of 
semaphorins for cell replacement therapy, such as in the recent approaches on PD 
[105], or the alternative new drug developments to target specific semaphorin-
induced kinases, such as in AD [67]. All these new treatment alternatives emerged 
in the recent years from the advances in understanding semaphorin-mediated 
mechanisms on human diseases. In addition, semaphorins have been recently 
pointed as the center for new therapeutic strategies using blocking antibodies. 
For example, the VX15/2503, an anti-Sema4D antibody has been characterized 
for clinical development on MS, Huntington’s disease, and cancer [157]. LaGanke 
et al. carried out a phase 1 study providing evidence that the VX15/2503 anti-
semaphorin 4D antibody administered at various doses was safe and tolerated in 
patients with MS [158]. It is expected in following years that new breakthroughs 
will further highlight semaphorin function in neurodegenerative conditions and 
contribute to future therapeutic strategies.
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